Vivek Subbiah: Awesome poster presentation on Epha2 targeting by our amazing Dr. Elisa Fontana
Vivek Subbiah shared on LinkedIn:
“Kudos to our amazing Sarah Cannon Research Institute Phase 1 clinical trial colleagues for the presentations at the Triple Targets23 meeting.
Awesome poster presentation on Epha2 targeting by our amazing Dr. Elisa Fontana, MD, PhD, Hospital Medical Director of the Sarah Cannon Research Institute in London, UK.
Congrats to Dr. Gerald Falchook, MD Sarah Cannon at HealthONE, Denver for presenting a late breaking abstracts poster on Phase 1 trial results of the Monocarboxylate inhibitor (MCTi) in combination with capecitabine in platinum resistant ovarian cancer. Interesting metabolic pathway target.”
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023